FENTANYL
Headache
University Medical Center of Southern NevadaSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Headache cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Topamax University of Minnesota | Phase 4 | BBB |
Treximet® Danish Headache Center | Phase 4 | BBB |
LIDOCAINE Daniel A Tonetti, MD | Phase 4 | BBB |
Prochlorperazine Wake Forest University Health Sciences | Phase 4 | BBB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE HCA Florida North Florida Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
FENTANYL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →